C1-Inhibitor and Its Genetic Alterations in Hereditary Angioneurotic Edema

References

• Lepow I. H., Ratnoff O. D., Rosen F. S., Pillemer L. Observations on a proesterase associated with partially purified first component of human complement (C'1). Proc. Soc. Exp. Biol. Med. 1956; 92: 32–37
   PubMed Web of Science ®Google Scholar
• Ratnoff O. D., Lepow I. H. Some properties of an esterase derived from preparations of the first component of complement. J. Exp. Med. 1957; 106: 327–343
   PubMed Web of Science ®Google Scholar
• Lepow I. H., Ratnoff O. D., Levy L. R. Studies on the activation of a proesterase associated with partially purified first component of human complement. J. Exp. Med. 1958; 107: 451–474
   PubMed Web of Science ®Google Scholar
• Levy L. R., Lepow I. H. Assay and properties of serum inhibitor of C'1 esterase. Proc. Soc. Exp. Biol. Med. 1959; 101: 608–611
   PubMed Web of Science ®Google Scholar
• Pensky J., Levy L. R., Lepow I. H. Partial purification of a serum inhibitor of C'1 esterase. J. Biol. Chem. 1961; 236: 1674–1679
   PubMed Web of Science ®Google Scholar
• Schultze H. E., Heide K., Haupt H. Uber ein bisher unbekanntes saures alpha-2 glykoprotein. Naturwissenschafien 1962; 49: 133–134
   Google Scholar
• Pensky J., Schwick H. G. Human serum inhibitor of C'1-esterase: identity with alpha 2-neura-minoglycoprotein. Science 1967; 163: 698–699
   Web of Science ®Google Scholar
• Haupt H., Heimburger N., Kranz T., Schwick H. G. Ein Beitrag zur Isolierung und Charakterisierung des C1-Inaktivators aus Humanpiasma. Eur. J. Biochem. 1970; 17: 254–261
   PubMedGoogle Scholar
• Donaldson V. H. Studies on the activation of a serum esterase with ether and its relationship to C'1 esterase. J. Clin. Invest. 1961; 40: 673–683
   PubMed Web of Science ®Google Scholar
• Donaldson V. H., Evans R. R. Absence of an enzyme inhibitor in hereditary angioneurotic edema. J. Lab. Clin. Med. 1961; 58: 812
   Web of Science ®Google Scholar
• Donaldson V. H., Evans R. R. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor in C'1-esterase. Am. J. Med. 1963; 35: 37–44
   PubMed Web of Science ®Google Scholar
• Ziccardi R. J. A new role for C1-inhibitor in hemostasis: control of activation of the first component of human complement. J. Immunol. 1982; 128: 2505–2508
   PubMed Web of Science ®Google Scholar
• Ziccardi R. J. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism. J. Immunol. 1982; 128: 2500–2504
   PubMed Web of Science ®Google Scholar
• Haines A. L., Lepow I. H. Studies on human C'1 esterase. I. Purification and enzymatic properties. J. Immunol. 1964; 92: 456–467
   PubMed Web of Science ®Google Scholar
• Donaldson V. H., Rosen F. S. Action of complement in hereditary angioneurotic edema: the role of C'1-esterase. J. Clin. Invest. 1964; 45: 2204–2213
   Google Scholar
• Forbes C. D., Pensky J., Ratnoff O. D. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J. Lab. Clin. Med. 1970; 76: 809–815
   PubMed Web of Science ®Google Scholar
• Ratnoff O. D., Pensky J., Ogston D., Naff G. B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor and the C1r subcomponent of the first component of complement by serum C1 esterase inhibitor. J. Exp. Med. 1969; 129: 315–331
   PubMed Web of Science ®Google Scholar
• Booth N. A., Walker E., Maughan R., Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: tPA circulates as complexes with C1 inhibitor and PAI-1. Blood 1987; 69: 1600–1604
   PubMed Web of Science ®Google Scholar
• Bennett B., Croll A., Ferguson K., Booth N. A. Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor. Blood 1990; 75: 671–676
   PubMed Web of Science ®Google Scholar
• Faulmann E. L., Young M., Boyle M. D. P. Inactivation of the proteolytic activity of mouse nerve growth factor by human C1-inhibitor. J. Immunol. 1987; 138: 4336–4340
   PubMed Web of Science ®Google Scholar
• Green L. A., Shooter E. M., Varon S. Subunit interaction and enzymatic activity of mouse 7S nerve growth factor. Biochemistry 1969; 8: 3735–3741
   PubMed Web of Science ®Google Scholar
• Dunbar J. C., Bradshaw R. A. Nerve growth factor biosynthesis: isolation and characterization of a guinea pig prostate kallikrein. J. Cell. Biochem. 1985; 29: 309–319
   PubMed Web of Science ®Google Scholar
• Bock S. C., Skriver K., Nielsen E., Thørgeson H-C., Wiman B., Donaldson V. H., Eddy R. L., Marrinan J., Radziejewska E., Huber R., Shows T. B., Magnusson S. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986; 25: 4292–4301
   PubMed Web of Science ®Google Scholar
• Davis A. E., III. C1 inhibitor and hereditary angioneurotic edema. Annu. Rev. Immunol. 1988; 6: 595–628
   PubMed Web of Science ®Google Scholar
• Salvesen G. S., Catanese J. J., Kress L. E., Travis J. Primary structure of the reactive site of human C1-inhibitor. J. Biol. Chem. 1985; 260: 2432–2436
   PubMed Web of Science ®Google Scholar
• Johnson A. M., Alper C. A., Rosen F. S., Craig J. M. C1-inhibitor: Evidence for decreased hepatic synthesis in hereditary angioneurotic edema. Science 1971; 173: 553–554
   PubMed Web of Science ®Google Scholar
• Bensa J. C., Reboul A., Colomb M. G. Biosynthesis in vitro of complement subcomponents C1q, C1s and C1-inhibitor by resting and stimulated human monocytes. Biochem. J. 1983; 216: 385–392
   PubMed Web of Science ®Google Scholar
• Katz Y., Strunk R. C. Synthesis and regulation of C1 inhibitor in human skin fibroblasts. J. Immunol. 1989; 142: 2041–2045
   PubMed Web of Science ®Google Scholar
• Randazzo B. P., Dattwyler R. J., Kaplan A. R., Ghebrehiwet B. Synthesis of C1 inhibitor (C1-INA) by a human monocyte-like cell line, U-937. J. Immunol. 1985; 135: 1313–1319
   PubMed Web of Science ®Google Scholar
• Morris K. M., Aden D. E., Knowles B. B., Colton H. R. Complement biosynthesis by the human hepatoma-derived cell line HepG2. J. Clin. Invest. 1982; 70: 906–913
   PubMed Web of Science ®Google Scholar
• Prandini M. H., Reboul A., Colomb M. G. Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s. Biochem. J. 1986; 237: 93–98
   PubMed Web of Science ®Google Scholar
• Lotz M., Zuraw B. L. Interferon-gamma is a major regulator of C1-inhibitor synthesis by human blood monocytes. J. Immunol. 1987; 139: 3382–3387
   PubMed Web of Science ®Google Scholar
• Donaldson V. H., Olivi L., Radziejewska E., Bock S. C., Wagner C. J. Human umbilical endothelial cells produce C1-inhibitor mRNA and secrete C1-inhibitor. Behring Inst. Mitt. 1989; 84: 194
   Google Scholar
• Schmaier A. H., Murray S. C., Heda G. D., Farber A., Kuo A., McCrae K., Cines D. B. Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J. Biol. Chem. 1989; 264: 18173–18179
   PubMed Web of Science ®Google Scholar
• Reboul A., Prandini M. H., Colomb M. G. Proteolysis and deglycosylation of human C1 inhibitor. Effect on functional properties. Biochem. J. 1987; 244: 117–121
   PubMed Web of Science ®Google Scholar
• Minta J. O. The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. J. Immunol. 1981; 126: 245–249
   PubMed Web of Science ®Google Scholar
• Lepow I. H., Naff G. B., Todd E. W., Pensky J., Hinz C. F., Jr. Chromatographic resolution of the first component of human complement into three activities. J. Exp. Med. 1963; 117: 983–1008
   PubMed Web of Science ®Google Scholar
• Naff G. B., Ratnoff O. D. The enzymatic nature of C1r. Conversion of C1s to C'1 esterase and digestion of amino acid esters by C1r. J. Exp. Med. 1968; 128: 571–593
   PubMed Web of Science ®Google Scholar
• Sim R. B., Reboul A., Arlaud G. J., Villiers C. L., Colomb M. G. Interaction of 125-labelled complement subcomponents C1r and C1s with protease inhibitors in plasma. FEBSLett. 1979; 97: 111–115
   PubMed Web of Science ®Google Scholar
• Ziccardi R. J. The role of immune complexes in the activation of the first component of human complement. J. Immunol. 1984; 132: 283–288
   PubMed Web of Science ®Google Scholar
• Laurell A-B., Johnson U., Mårtensson U., Sjöholm A. G. Formation of complexes composed of C1r, C1s, and C1-inactivator in human serum on activation of C1. Acta Pathol. Microbiol. Scand. 1978; 86: 299–306
   Google Scholar
• Ziccardi R. J., Cooper N. R. Active disassembly of the first component of complement, C-1 by C-1 inactivator. J. Immunol. 1979; 123: 788–792
   PubMed Web of Science ®Google Scholar
• Laurell A-B., Mårtensson U., Sjöholm A. G. C1 subcomponent complexes in normal and pathological sera studied by crossed immunoelectrophoresis. Acta Pathol. Microbiol. Scand. 1976; 84: 455–464
   Google Scholar
• Donaldson V. H. C'1 activation in hereditary angioneurotic edema plasma: role of urokinase and inhibitors. J. Appl. Physiol. 1968; 25: 416–424
   Web of Science ®Google Scholar
• Donaldson V. H. Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro. The role of Hageman factor, a clot-promoting agent. J. Exp. Med. 1968; 127: 411–429
   PubMed Web of Science ®Google Scholar
• Ziccardi R. J. A. new role for C1-inhibitor in homeostasis: control of activation of the first component of human complement. J. Immunol. 1982; 128: 2505–2508
   PubMed Web of Science ®Google Scholar
• Tenner A. J., Frank M. M. Activator-bound C1 is less susceptible to inactivation by C1 inhibition that is fluid phase C1. J. Immunol. 1986; 137: 625–630
   PubMed Web of Science ®Google Scholar
• Gigli I., Mason J. W., Colman R. W., Austen K. F. Interaction of plasma kallikrein with the C1-inhibitor. J. Immunol. 1970; 104: 574–581
   PubMed Web of Science ®Google Scholar
• Harpel P. C., Cooper N. R. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interactions with C1s, plasmin and trypsin. J. Clin. Invest. 1975; 55: 593–604
   PubMed Web of Science ®Google Scholar
• Aoki N., Moroi M., Matsuda M, Tachiya K. The behavior of alpha 2-plasmin inhibitor in fibrinolytic states. J. Clin. Invest. 1977; 60: 361–369
   PubMed Web of Science ®Google Scholar
• Harpel P. C. Alpha 2-plasmin inhibitor and alpha 2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J. Clin. Invest. 1981; 68: 46–55
   PubMed Web of Science ®Google Scholar
• Weiss V., Engel J. Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement. Hoppe Seylers Z. Physiol. Chem. 1983; 364: 295–301
   PubMedGoogle Scholar
• Chesne S., Villiers C. L., Arlaud G. J., LaCroix M. B., Colomb M. G. Fluid-phase interaction of C1-inhibitor (C1-INH) and the subcomponents C1r and C1s of the first component of complement, C1. Biochem. J. 1982; 201: 61–70
   PubMed Web of Science ®Google Scholar
• Patston P. A., Gettins R., Beechem J., Schapira M. Mechanism of serpin action: Evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 1991; 30: 8876–8882
   PubMed Web of Science ®Google Scholar
• Schapira M., Scott C. F., Colman R. W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. 1982; 69: 462–468
   PubMed Web of Science ®Google Scholar
• Van der Graff F., Koedam J. A., Bouma B. N. Inactivation of kallikrein in human plasma. J. Clin. Invest. 1983; 71: 149–158
   PubMed Web of Science ®Google Scholar
• Lewin M. F., Kaplan A. P., Harpel P. C. Studies of C1-inactivator-plasma kallikrein complexes in purified systems and in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J. Biol. Chem. 1983; 258: 6415–6421
   PubMed Web of Science ®Google Scholar
• Harpel P. C., Lewin M. F., Kaplan A. P. Distribution of plasma kallikrein between C1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J. Biol. Chem. 1985; 260: 4257–4263
   PubMed Web of Science ®Google Scholar
• De Agostini A., Lijnen H. R., Pixley R. A., Colman R. W., Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C1-inhibitor. J. Clin. Invest. 1984; 73: 1542–1549
   PubMed Web of Science ®Google Scholar
• Pixley R. A., Schapira M., Colman R. W. The regulation of human factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. 1985; 260: 1723–1729
   PubMed Web of Science ®Google Scholar
• Wachtfogel Y. T., Harpel P. C., Edmunds L. H., Jr, Colman R. W. Formation of Cls-Cl-inhibitor, kallikrein-Cl-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 468–471
   PubMed Web of Science ®Google Scholar
• Kaufman N., Page J. D., Pixley R. A., Schein R., Schmaier A. H., Colman R. W. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991; 77: 2660–2667
   PubMed Web of Science ®Google Scholar
• Nuijens J. H., Huijbregts C. M., Eerenberg-Belmer A. J. M., Abbink J. J., Strack van Schijndel R. J. M., Felt-Bersma R. J. K., Thijs L. G., Hack C. E. Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood 1988; 72: 1841–1848
   PubMed Web of Science ®Google Scholar
• Donaldson V. H., Rosen F. S. Hereditary angioneurotic edema: a clinical survey. Pediatrics 1966; 37: 1017–1027
   PubMed Web of Science ®Google Scholar
• Donaldson V. H., Ratnoff O. D., Dias Da Silva W., Rosen F. S. Permeability-increasing activity in hereditary angioneurotic edema plasma. J. Clin. Invest. 1969; 48: 642–653
   PubMed Web of Science ®Google Scholar
• Klemperer M. R., Donaldson V. H., Rosen F. S. Effect of C'1 esterase on vascular permeability in man: Studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema. J. Clin. Invest. 1968; 47: 604–611
   PubMed Web of Science ®Google Scholar
• Strang C. J., Auerback H. S., Rosen F. S. C1s-induced vascular permeability in C2-deficient guinea pigs. J. Immunol. 1986; 137: 631–635
   PubMed Web of Science ®Google Scholar
• Donaldson V. H., Rosen F. S., Bing D. H. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans. Assoc. Am. Physicians 1977; 90: 174–183
   PubMedGoogle Scholar
• Fields T., Ghebrehiwet B., Kaplan A. P. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J. Allergy Clin. Immunol. 1983; 72: 54–60
   PubMed Web of Science ®Google Scholar
• Schapira M., Silver L. D., Scott C. E., Schmaier A. H., Prograis L. J., Jr, Curd J. G., Colman R. W. Prekallikrein activation and high-molecular-weight-kininogen consumption in hereditary angioedema. N. Engl. J. Med. 1983; 308: 1050–1053
   PubMed Web of Science ®Google Scholar
• Landerman N. S., Webster M. E., Becker E. L., Ratcliffe H. E. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J. Allergy 1962; 33: 330–341
   PubMedGoogle Scholar
• Rosen F. S., Charache P., Pensky J., Donaldson V. H. Hereditary angioneurotic edema: two genetic variants. Science 1965; 148: 957–958
   PubMed Web of Science ®Google Scholar
• Rosen F. S., Alper C. A., Pensky J., Klemperer M. R., Donaldson V. H. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J. Clin. Invet. 1971; 50: 2143–2149
   PubMed Web of Science ®Google Scholar
• Quincke H. über akutes umschreibenes Hautodem, Monatschefte fur praktische. Dermatology 1882; 1: 129–131
   Google Scholar
• Osier W. Hereditary angio-neurotic oedema. Am. J. Med. Sci. 1888; 95: 362–367
   Google Scholar
• Donaldson V. H., Harrison R. A., Rosen F. S., Bing D. H., Kindness G., Canar J., Wagner C. J., Awad S. Variability in purified dysfunctional C1-inhibitor proteins from patients with hereditary angioneurotic edema. J. Clin. Invest. 1985; 75: 124–132
   PubMed Web of Science ®Google Scholar
• Donaldson V. H., Wagner C. J., Tsuei B., Kindness G., Bing D. H., Harrison R. A., Rosen F. S. Interactions of plasma kallikrein and C1s with normal and dysfunctional C1-inhibitor proteins from patients with hereditary angioneurotic edema: Analytic gel studies. Blood 1987; 69: 1096–1011
   PubMed Web of Science ®Google Scholar
• Donaldson V. H., Mitchell B. H., Everson B., Ratnoff O. D. Interactions of C1-inhibitors from normal persons and patients with Type II hereditary angioneurotic edema with purified activated Hageman factor (factor XIIa). Blood 1990; 75: 911–921
   PubMed Web of Science ®Google Scholar
• Quastel M., Harrison R., Cicardi M., Alper C. A., Rosen F. S. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J. Clin. Invest. 1983; 71: 1041–1046
   PubMed Web of Science ®Google Scholar
• Lachmann P. J., Rosen E. S. The catabolism of C1 inhibitor and the pathogenesis of hereditary angioedema. Acta Pathol. Microbiol. Immunol. Scand. Suppl 1984; 284: 35–39
   PubMedGoogle Scholar
• Woo R., Lachmann P. J., Harrison R. A., Amos N., Cooper C., Rosen F. S. Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activated proteases. Clin. Exp. Immunol. 1985; 61: 1–8
   PubMed Web of Science ®Google Scholar
• Cugno M., Nuijens J., Hack E., Eerenberg A., Frangi D., Agostoni A., Cicardi M. Plasma levels of C1-inhibitor complexes and cleaved C1-inhibitor in patients with hereditary angioneurotic edema. J. Clin. Invest. 1990; 85: 1215–1220
   PubMed Web of Science ®Google Scholar
• Kramer J., Katz Y., Rosen F. S., Davis A. E., III, Strunk R. C. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. J. Clin. Invest. 1991; 87: 1614–1620
   PubMed Web of Science ®Google Scholar
• Cicardi M., Igarashi T., Rosen F. S., Davis A. E., III. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J. Clin. Invest. 1987; 79: 698–702
   PubMed Web of Science ®Google Scholar
• Lappin D. E., McPhaden A. R., Yap P. L., Carter P. E., Birnie G. D., Fothergill J. E., Whaley K. Monocyte C1-inhibitor synthesis in patients with C1-inhibitor deficiency. Eur. J. Clin. Invest. 1989; 19: 45–52
   PubMed Web of Science ®Google Scholar
• Que B. G., Petra P. H. Isolation and analysis of a cDNA coding for human C1-inhibitor. Biochem. Biophys. Res. Commun. 1986; 137: 620–625
   PubMed Web of Science ®Google Scholar
• Davis A. E., III, Whitehead A. S., Harrison R. A., Dauphinais A., Bruns G. A. R., Cicardi M., Rosen E. S. Human inhibitor of the first component of complement, C1: Characterization of cDNA clones and localization of the gene to chromosome 11. Proc. Natl. Acad. Sci. USA 1986; 83: 3161–3165
   PubMed Web of Science ®Google Scholar
• Davis A. E., III. Hereditary and acquired deficiencies of C1-inhibitor. Immunodefic. Rev. 1989; 1: 207–226
   PubMedGoogle Scholar
• Carter P. E., Duponchel C., Tosi M., Fothergill J. E. Complete nucleotide sequence of the gene for human C1-inhibitor with an unusually high density of Alu elements. Eur. J. Biochem. 1991; 197: 301–308
   PubMedGoogle Scholar
• Stoppa-Lyonnet D., Tosi M., Laurent J., Sobel A., Lagrue G., Meo T. Altered C1 inhibitor genes in type I hereditary angioneurotic edema. N. Engl. J. Med. 1987; 317: 1–6
   PubMed Web of Science ®Google Scholar
• Tosi M., Stoppa-Lyonnet D., Carter P., Meo T. Molecular defects of the C1-inhibitor gene in hereditary angioedema. Behring Inst. Mitt. 1989; 84: 173–179
   Google Scholar
• Stoppa-Lyonnet D., Duponchel C., Meo T., Laurent J., Carter P. E., Arala-Chavez M., Cohen J. H. M., Dewald G., Goetz J., Hauptmann G., Lagrue G., Lesavre R., Lopaz-Trascasa M., Mistano G., Moraine C., Sobel A., Spath P. J., Tosi M. Recombinational biases in the rearranged C1-inhibitor genes of hereditary angioedema patients. Am. J. Hum. Genet. 1991; 49: 1055–1062
   PubMed Web of Science ®Google Scholar
• Carter P. E., Dunbar B., Fothergill J. E. Genomic cDNA cloning of the human C1 inhibitor. Intronexon junctions and comparison with other serpins. Eur. J. Biochem. 1988; 173: 163–169
   PubMedGoogle Scholar
• Cicardi M., Igarashi T., Kim M. S., Frangi D., Agostoni A., Davis A. E., III. Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema. J. Clin. Invest. 1987; 80: 1640–1643
   PubMed Web of Science ®Google Scholar
• Ariga T., Carter P. E., Davis A. E., III. Recombinations between Alu repeat sequences that result in partial deletions within the C1-inhibitor gene. Genomics 1990; 8: 607–613
   PubMed Web of Science ®Google Scholar
• Stoppa-Lyonnet D., Carter P. E., Meo T., Tosi M. Clusters of intragenic Alu repeats predispose the human C1 inhibitor locus to deleterious rearrangements. Proc. Natl. Acad. Sci. USA 1990; 87: 1551–1555
   PubMed Web of Science ®Google Scholar
• McPhaden A. R., Birnie G. D., Whaley K. Restriction fragment length polymorphism analysis of the C1-inhibitor gene in hereditary C1-inhibitor deficiency. Clin. Genet. 1991; 39: 161–171
   PubMed Web of Science ®Google Scholar
• Jelinek W. R., Schmid C. W. Repetitive sequences in eukaryotic DNA and their expression. Annu. Rev. Biochem. 1982; 51: 813–844
   PubMed Web of Science ®Google Scholar
• Ullu E., Tschudi C. Alu sequences are processed 7SL RNA genes. Nature 1984; 312: 171–172
   PubMed Web of Science ®Google Scholar
• Davis A. E., III, Bissler J. J., Aulak K. S. Genetic defects in the C1 inhibitor gene. Complement Profiles 1992., In press.)
   Google Scholar
• Bissler J. J., Donaldson V. H., Cicardi M., Davis A. E., III. Intra-exonic deletions and insertions in the C1 inhibitor gene. FASEB J. 1992; 6: A1452, No. 4, (Abstract)
   Web of Science ®Google Scholar
• Ariga T., Igarashi T., Ramesh N., Parad R., Cicardi M., Davis A. E., III. Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon. J. Clin. Invest. 1989; 83: 1888–1893
   PubMed Web of Science ®Google Scholar
• Verpy E., Laurent J., Spath P. J., Meo T., Tosi M. Clustering of point mutations downstream of the C1-inhibitor reactive site in hereditary angioedema patients. Complement Inflamm. 1991; 8: 296, (Abstract)
   Google Scholar
• Siddique Z. M., McPhaden A. R., Whaley K. A frameshift mutation giving rise to a premature stop codon in exon 8 of the C1-inhibitor gene of a Type I HAE patient. Clin. Exp. Immunol. 1991; 86: 11, (Abstract)
   Google Scholar
• Frangi D., Cicardi M., Sica A., Colotta E., Agostoni A., Davis A. E., III. Nonsense mutations affect C1-inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema. J. Clin. Invest. 1991; 88: 755–759
   PubMed Web of Science ®Google Scholar
• Aulak K. S., Cicardi M., Harrison R. A. Identification of a new PI residue mutation (444 ARG←Ser) in a dysfunctional C1-inhibitor protein contained in a type II hereditary angioedema plasma. Febs Lett. 1990; 266: 13–16
   PubMed Web of Science ®Google Scholar
• Donaldson V. H., Bissler J. J. C1-inhibitors and their genes: An update. J. Lab. Clin. Med. 1992; 119: 330–333
   PubMed Web of Science ®Google Scholar
• Skriver K., Radziejewska E., Silbermann J. A., Donaldson V. H., Bock S. C. CpG mutations in the reactive site of human C1 inhibitor. J. Biol. Chem. 1989; 264: 3066–3071
   PubMed Web of Science ®Google Scholar
• Cooper D. N., Youssoufian H. The CpG dinucleotide and human genetic disease. Hum. Genet. 1988; 78: 151–155
   Web of Science ®Google Scholar
• Frangi D., Aulak K. S., Cicardi M., Harrison R. A., Davis A. E., III. A dysfunctional C1 inhibitor protein with a new reactive center mutation (ARG 444←Leu). Febs Lett. 1992; 301: 34–46
   PubMed Web of Science ®Google Scholar
• Parad R. B., Kramer J., Strunk R. C., Rosen F. S., Davis A. E., III. Dysfunctional C1 inhibitor Ta:deletion of Lys-251 results in acquisition of an N-glycosylation site. Proc. Natl. Acad. Sci. U. S. A. 1990; 88: 6786–6790
   Google Scholar
• Skriver K., Wikoff W. R., Patston P. A., Tausk F., Schapira M., Kaplan A. P., Bock S. C. Substrate properties of C1 inhibitor Ma (Alanine 434←Glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor inhibitor/substrate status. J. Biol. Chem. 1991; 266: 9216–9221
   PubMed Web of Science ®Google Scholar
• Levy N. J., Ramesh N., Cicardi M., Harrison R. A., Davis A. E., III. Type H hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1-inhibitor gene. Proc. Natl. Acad. Sci. USA 1990; 87: 265–268
   PubMed Web of Science ®Google Scholar
• Davis A. E., III, Aulak K. S., Parad R. B., Stecklein H. P., Eldering E., Hack C. E., Kramer J., Strunk R. C., Rosen F. S. Characterization and expression of C1-inhibitor non-reactive center mutations. Complement Inflamm. 1991; 8: 138, (Abstract)
   Google Scholar
• Stead N., Kaplan A. R., Rosenberg R. D. Inhibition of activated factor XII by antithrombin-heparin cofactor. J. Biol. Chem. 1976; 251: 6481–6488
   PubMed Web of Science ®Google Scholar
• Saito H., Goldsmith G. H., Moroi M., Aoki N. Inhibitory spectrum of alpha 2-plasmin inhibitor. Proc. Natl. Acad. Sci. USA 1979; 76: 2013–2017
   PubMed Web of Science ®Google Scholar
• Harpel P. C. Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein. J. Exp. Med. 1970; 132: 329–352
   PubMed Web of Science ®Google Scholar
• Venneröd A. M., Laake K. Inhibition of purified plasma kallikrein by antithrombin III and heparin. Thromb. Res. 1975; 7: 223–226
   PubMed Web of Science ®Google Scholar
• Fritz H., Wunderer G., Kummer K., Heimburger N., Werle E. Alpha 1-antitrypsin und C1-inaktivator: Progressiv-inhibitoren für serumkallikreine von mensch und schwein. Hoppe Seylers Z. Physiol. Chem. 1972; 353: 906–910
   PubMedGoogle Scholar
• McConnell D. J. Inhibitors of kallikrein in human plasma. J. Clin. Invest. 1972; 51: 1611–1623
   PubMed Web of Science ®Google Scholar
• Gans H., Tan B. H. Alpha 1-antitrypsin, an inhibitor for thrombin and plasmin. Clin. Chim. Acta 1967; 17: 111–117
   PubMed Web of Science ®Google Scholar
• Moroi M., Aoki N. Isolation and characterization of α2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J. Biol. Chem. 1976; 251: 5956–5965
   PubMed Web of Science ®Google Scholar
• Ganrot P. O. Interaction of plasmin and trypsin with alpha 2-macroglobulin. Acta Chem. Scand. 1967; 21: 602–608
   Google Scholar
• Heck L. W., Kaplan A. R. Substrates of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by alpha 1-antitrypsin. J. Exp. Med. 1974; 140: 1615–1630
   PubMed Web of Science ®Google Scholar
• Skriver K., Wikoff W. R., Stoppa-Lyonnet D., Donaldson V. H., Bock S. C. 1992, Unpublished observations.
   Google Scholar
• Cicardi M., Bergamaschini L., Marasini B., Boccassini G., Tucci A., Agostoni A. Hereditary angioedema: an appraisal of 104 cases. Am. J. Med. Sci. 1982; 284: 2–9
   PubMed Web of Science ®Google Scholar
• Bergamaschini L., Cicardi M., Tucci A., Gardinali M., Frangi D., Valle C., Agostoni A. C1 INH concentrate in the therapy of hereditary angioedema. Allergy 1983; 38: 81–84
   PubMed Web of Science ®Google Scholar
• Lundh B., Laurell A-B., Wetterqvist H., White T., Granerus G. A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid. Studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism. Clin. Exp. Immunol. 1968; 3: 733–745
   PubMedGoogle Scholar
• Frank M. M., Sergent J. S., Kane M. A., Ailing D. W. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N. Engl. J. Med. 1972; 286: 808–812
   PubMed Web of Science ®Google Scholar
• Marasini B., Cicardi M., Martignoni G. C., Agostoni A. Treatment of hereditary angioedema. Klin. Wochenschr. 1978; 56: 819–823
   PubMedGoogle Scholar
• Sheffer A. L., Austen K. F., Rosen F. S. Tranexamic acid therapy in hereditary angioneurotic edema. N. Engl. J. Med. 1972; 287: 452–454
   PubMed Web of Science ®Google Scholar
• Sim T. C., Grant J. A. Hereditary angioedema: its diagnostic and management perspectives. Am. J. Med. 1990; 88: 656–664
   PubMed Web of Science ®Google Scholar
• Spaulding W. B. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann. Intern. Med. 1960; 53: 739–745
   Web of Science ®Google Scholar
• Gelfand J. A., Sherins R. J., Ailing D. W., Frank M. M. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N. Engl. J. Med. 1976; 295: 1444–1448
   PubMed Web of Science ®Google Scholar
• Hosea S. W., Santaella M. L., Brown E. J., Berger M., Katusha K., Frank M. M. Long-term therapy of hereditary angioedema with danazol. Ann. Intern. Med. 1980; 93: 809–812
   PubMed Web of Science ®Google Scholar
• Pitts J. S., Donaldson V. H., Forristal J., Wyatt R. J. Remissions induced in hereditary angioneurotic edema with an attenuated androgen (danazol): correlation between concentrations of C1-inhibitor and the fourth and second components of complement. J. Lab. Clin. Med. 1978; 92: 501–507
   PubMed Web of Science ®Google Scholar
• Donaldson V. H. Danazol. Am. J. Med. 1989; 87(3N): 49N–55, N
   Web of Science ®Google Scholar
• Bagheri S. A., Boyer J. L. Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury. Ann. Intern. Med. 1974; 81: 610–618
   PubMed Web of Science ®Google Scholar